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BACKGROUND: The Radiation Therapy Oncology Group (RTOG) trial 97-14 revealed no difference between radiation delivered for pain-
ful bone metastases at a dose of 8 gray (Gy) in 1 fraction (single-fraction radiotherapy [SFRT]) and 30 Gy in 10 fractions (multifraction
radiotherapy [MFRT]) in pain relief or narcotic use 3 months after randomization. SFRT for painful vertebral bone metastases (PVBM)
has not been well accepted, possibly because of concerns about efficacy and toxicity. In the current study, the authors evaluated the
subset of patients that was treated specifically for patients with PVBM. METHODS: PVBM included the cervical, thoracic, and/or lumbar
spine regions. Among patients with PVBM, differences in retreatment rates and in pain relief, narcotic use, and toxicity 3 months after
randomization were evaluated. RESULTS: Of 909 eligible patients, 235 (26%) had PVBM. Patients with and without PVBM differed in
terms of the percentage of men (55% vs 47%, respectively; P ¼ .03) and the proportion of patients with multiple painful sites (57% vs
38%, respectively; P < .01). Among those with PVBM, more patients who received MFRT had multiple sites treated (65% vs 49% for
MFRT vs SFRT, respectively; P ¼ .02). There were no statistically significant treatment differences in terms of pain relief (62% vs 70%
for MFRT vs SFRT, respectively; P ¼ .59) or freedom from narcotic use (24% vs 27%, respectively; P ¼ .76) at 3 months. Significant dif-
ferences in acute grade 2 through 4 toxicity (20% vs 10% for MFRT vs SFRT, respectively; P ¼ .01) and acute grade 2 through 4 gas-
trointestinal toxicity (14% vs 6%, respectively; P ¼ .01) were observed at 3 months, with lower toxicities seen in the patients treated
with SFRT. Late toxicity was rare. No myelopathy was recorded. SFRT produced higher 3-year retreatment rates (5% vs 15%; P ¼ .01).
CONCLUSIONS: Results for the subset of patients with PVBM in the RTOG 94-17 randomized controlled trial were comparable to
those for the entire population. SFRT produced less acute toxicity and a higher rate of retreatment than MFRT. SFRT and MFRT
resulted in comparable pain relief and narcotic use at 3 months. Cancer 2013;119:888-96.VC 2012 American Cancer Society.
KEYWORDS: radiation oncology, bone metastases, palliative care, pain management, supportive care, metastases, single-fraction
radiation, stereotactic radiation therapy, spine malignancy, late effects.
INTRODUCTION
Pain secondary to osseous metastases is a serious problem in many patients with stage IV cancer. There are several options
for the treatment of painful bone metastases. Radiation therapy is an effective treatment, providing pain relief and reduc-
ing the need for narcotics and other analgesics to manage symptomatic bone metastases. Many randomized trials have
demonstrated that various dose/fractionation schedules of radiation can provide comparable pain relief.1-3 Several
randomized controlled trials have indicated equivalency in endpoints measured, such as pain relief and need for narcotic
use after the delivery of a single, higher dose of radiation compared with several smaller doses of radiation delivered over
10 treatments.1-3
In 2005, Hartsell et al4 reported on Radiation Therapy Oncology Group (RTOG) Study 97-14, which investigated
patients with breast cancer and prostate cancer who were diagnosed with painful osseous metastases and had an expected
median survival of at least 3 months. Those patients received palliative radiation and were randomized to 2 different
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fractionation schedules: 8 Gray (Gy) in a single fraction (8
Gy/1) versus 30 Gy delivered in 10 fractions (30 Gy/10).
The results from that study revealed no substantive differ-
ences in the endpoints of pain relief and narcotic use 3
months postrandomization. The 8 Gy/1 group had a
lower incidence of acute toxicities but higher rates of
retreatment than the 30 Gy/10 group. RTOG 97-14
included patients who had osseous metastases to a wide
range of bones throughout the body, excluding the skull,
hands, and feet. Despite overwhelming evidence that
equivalent pain relief from painful bone metastases could
be achieved from a single radiation treatment, practice
patterns among US radiation oncologists still favor a mul-
tifraction course of radiation.5-7
The United States radiation oncology community
has not well accepted single-fraction conventional radia-
tion (SFRT) for use in the treatment of painful vertebral
bone metastases, possibly because of provider concerns
about efficacy and toxicity. Radiation oncologists have
cited concerns about increased risks of acute gastrointesti-
nal (GI) toxicity, such as esophagitis, nausea, and vomit-
ing; late central nervous system (CNS) toxicity, such as
myelopathy; and potential greater needs for retreatment
as reasons not to use SFRT.
The use of a shorter course of radiation for support-
ive care in this palliative situation makes it easier for
patients and their caregivers to arrange for the logistics of
therapy. One or 2 visits to the treatment facility for plan-
ning and treatment save time and resources for patients,
caregivers, and health care providers compared with 10
visits. The concerns about efficacy and toxicity because of
8 Gy/1 vs 30 Gy/10 in patients who were treated specifi-
cally for painful vertebral bone metastases prompted a ret-
rospective subset analysis of patients from RTOG 97-14
who had painful vertebral bone metastases.
MATERIALS AND METHODS
Patient Population
Patients were randomized to receive 8 Gy/1 on 1 day or
30 Gy/10 over 2 weeks. Patients were treated for no more
than 3 separate painful sites (multiple spine sites were
allowed). Patients were identified as those with painful
vertebral bone metastases (PVBM) if any of the treated
sites were at the cervical, thoracic, or lumbar spine.
Patients who had spinal cord compression or a Karnofsky
performance status<40 were excluded from the study.
The Brief Pain Inventory (BPI) worst pain score
was used to assess pain response.8 Eligible patients had
a baseline BPI worst pain score 5 or a score <5 while
they were receiving a daily equivalent of 60 mg mor-
phine. Pain response was determined by the BPI worst
pain score at a follow-up assessment that occurred 3
months after the initiation of radiation. Pain response
was categorized as follows: 1) complete response–a
post-treatment pain score of 0; 2) partial response–a
post-treatment improvement of at least 2 points; 3) sta-
ble response–post-treatment pain score within 1 point
of the initial pain score; or 4) progression of pain–a
post-treatment increase of at least 2 points.
The BPI worst pain score does not incorporate nar-
cotic use. Narcotic use was assessed 3 months after the
start of radiation using the following criteria: 1) no pain
medication, 2) non-narcotic analgesics (aspirin, buffered
aspirin, acetaminophen, ibuprofen, and others), 3) mild
narcotics (0.5 g), 4), moderate narcotics (0.5-1.0 g), or
5) strong narcotics (1 g) per day.
The decision to retreat patients and the retreatment
dose and fractionation were left to the discretion of the
treating radiation oncologist. Retreatment was not per-
mitted within 4 weeks of completion of initial treatment
unless a patient experienced progressive pain.
Adverse events that occurred before 90 days after the
start of treatment were reported according to the Acute
Radiation Morbidity Scoring Criteria. and adverse events
that occurred at least 90 days after start of treatment were
reported according to the RTOG/European Organization
for Research and Treatment of Cancer (EORTC) Late
RadiationMorbidity Scoring Scheme.9
Statistical Methods
The chi-square test was used to test for treatment differen-
ces (8 Gy/1 vs 30 Gy/10) in the distribution of pain
response at the .05 significance level. The chi-square test
also was used to test for treatment differences in the distri-
bution of narcotic use at the .05 significance level.
Retreatment rates were estimated using the cumula-
tive incidence method to account for death as a competing
risk. Gray’s test was used to test for treatment differences
in retreatment rates at the .05 significance level (2-sided).
Overall survival was estimated using the Kaplan-Meier
method. The log-rank test was used to test for treatment
differences in overall survival at the .05 significance level
(2-sided). All data were analyzed using SAS statistical soft-
ware (version 9.1 for Windows; SAS Institute Inc., Cary,
NC).
RESULTS
RTOG 97-14 accrued 949 patients (909 eligible), of
which 235 had PVBM. Most patients received treatment
to the lumbar (51%) or thoracic (36%) spine. Patients
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also received radiation to the cervical spine or to multiple
spine sites. PVBM patients were similar to the general
RTOG 97-14 population (Table 1), although there were
some differences. PVBM patients were older (median age,
68 years vs 66 years for patients with nonvertebral bone
metastases [non-PVBM]; P < .01), were mostly men
(55% vs 47% of non-PVBM; P ¼ .03), and were more
likely to have received treatment at multiple painful sites
(57% vs 38% non-PBVM; P< .01).
Among patients with PVBM, most pretreatment
characteristics did not differ between patients who
received 8 Gy/1 or 30 Gy/10, as expected because of ran-
domization (Table 2). However, patients with PVBM
who received 30 Gy/10 were more likely to have multiple
treatment sites (65% vs 49% for patients who received 8
Gy/1; P¼ .02).
Treatment was appropriately delivered according to
protocol. A random sample of 71 patients (30%) was
selected for quality-assurance review. Ninety-three per-
cent of patients received treatment within protocol bor-
ders, 96% received the total protocol dose, 99% received
all fractions, and 99% did not have any treatment delays.
Patients received 4 to 9 megavoltage (MV) photons
(63%), 10 to 20 MV photons (23%), 60-Cobalt (11%),
Table 1. Pretreatment Characteristics for All Eligible Patients:
Radiation Therapy Oncology Group Trial 9714










Age: Median [range], y 66 [31-92] 68 [33-92] <.01
Treatment arm
8 Gy 336 (50) 124 (53) .45
30 Gy 338 (50) 111 (47)
Sex
Men 318 (47) 130 (55) .03
Women 356 (53) 105 (45)
Race/ethnicity
White 488 (72) 166 (71) .27
Black 101 (15) 41 (17)
Hispanic 34 (5) 6 (3)
Other 51 (8) 22 (9)
KPS
40-60 159 (23) 56 (24) .65
70-80 355 (53) 134 (57)
90-100 160 (24) 45 (19)
Receiving
bisphosphonates
Yes 170 (25) 51 (22) .28
No 504 (75) 184 (78)
Painful sites
Solitary 415 (62) 102 (43) <.01
Multiple 259 (38) 133 (57)
BPI worst pain
score, baseline
<5 15 (2) 3 (1) .39
5-6 194 (29) 60 (26)
7-10 465 (69) 172 (73)
Abbreviations: BPI, Brief Pain Inventory; Gy, Gray; KPS, Karnofsky perform-
ance status; RT, radiation therapy.
aP values were determined using the chi-square test for all variables
except age (t test).









Age: Median [range], y 69 [36-92] 68 [33-91] .85
Sex
Men 68 (55) 61 (55) .96
Women 55 (45) 50 (45)
Race/ethnicity
White 86 (69) 80 (72) .35
Black 26 (21) 15 (13)
Hispanic 2 (2) 4 (4)
Other 10 (8) 12 (11)
KPS
40-60 29 (23) 27 (24) .80
70-80 73 (59) 61 (55)
90-100 22 (18) 23 (21)
Receiving
bisphosphonates
Yes 23 (19) 28 (25) .22
No 101 (81) 83 (75)
Painful sites: Vertebral
and nonvertebral
Solitary 63 (51) 39 (35) .02
Multiple 61 (49) 72 (65)
Treatment site
Weight bearing 48 (39) 36 (32) .32
Nonweight bearing 76 (61) 75 (68)
Vertebral site
Cervical 12 (10) 7 (6) 0.78
Thoracic 44 (35) 40 (36)
Lumbar 63 (51) 58 (53)
Multiple sites 5 (4) 6 (5)
BPI worst pain score,
baseline
<5 2 (2) 1 (1) .68
5-6 34 (27) 26 (23)
7-10 88 (71) 84 (76)
Abbreviations: BPI, Brief Pain Inventory; Gy, Gray; KPS, Karnofsky perform-
ance status.
aP values were determined using the chi-square test for all variables
except age (t test).
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or other energies (3%). Acute and late adverse events were
minimal. For patients who received 8 Gy/1, there were no
grade 4 adverse events, there was 1 grade 3 acute nonhe-
matologic (lung) adverse event, and there were two grade
3 late nonhematologic (CNS) adverse events (grade 3
CNS adverse events were defined as neurologic findings
that required hospitalization for initial management). For
patients who received 30 Gy/10, there was 1 grade 4 acute
hematologic adverse event, 1 grade 4 late nonhematologic
(lung) adverse event, and there were 3 grade 3 acute non-
hematologic (GI) adverse events. Radiation myelopathy
was not reported in any patient. Significant treatment dif-
ferences (8 Gy/1 vs 30 Gy/10) in acute overall grade 2
through 4 toxicity (10% vs 20%, respectively; P ¼ .01)
and acute grade 2 through 4 GI toxicity (6% vs 14%,
respectively; P ¼ .01) were observed at 3 months, with
less toxicity in the 8 Gy/1 group.
No significant difference between treatment arms
was reported in narcotic use or pain response 3 months
after initiation of radiation (Tables 3 and 4). Sixty-three
percent of patients on each treatment arm reported mod-
erate or strong narcotic use (P ¼ .76). Seventy percent
and 62% of patients on the 8 Gy/1 and 30 Gy/10 treat-
ment arms, respectively, experienced a partial or complete
pain response (P¼ .59).
Patients who received 8 Gy/1 had significantly
higher retreatment rates at 3 years after their initial radia-
tion (15% vs 5%; P¼ .01), and differences were evident 3
months after their initial radiation course (Table 5). There
were no differences among patients who had cervical, tho-
racic, or multiple spine sites; the differences in retreatment
in the overall PVBM population were attributable to
patients who had lumbar spine metastases. Sixty-eight
percent (17 of 25 patients) of retreated patients were lum-
bar spine patients. There were no differences in overall
survival attributable to treatment. The median survival
was 9.3 months in the 8 Gy/1 treatment arm and 10.6
months in the 30 Gy/10 treatment arm (P ¼ .51).
Table 3. Narcotic Use 3 Months After the Start of Radiation Therapya
8-Gy Arm 30-Gy Arm
Narcotic Use at 3 Months No. % No. % Pb
All vertebral patients 84 100 89 100
None 17 20 15 17 .76
Analgesics 6 7 6 7
Mild narcotic 8 10 12 13
Moderate narcotic 21 25 17 19
Strong narcotic 32 38 39 44
Cervical spine patients 9 5
None 2 22 1 20 .86
Analgesics 1 11 0 0
Moderate narcotic 1 11 1 20
Strong narcotic 5 56 3 60
Thoracic spine patients 28 33
None 7 25 8 24 .97
Analgesics 4 14 3 9
Mild narcotic 3 11 3 9
Moderate narcotic 4 14 5 15
Strong narcotic 10 36 14 42
Lumbar spine patients 42 47
None 5 12 5 11 .13
Analgesics 1 2 3 6
Mild narcotic 3 7 9 19
Moderate narcotic 16 38 8 17
Strong narcotic 17 41 22 47
Patients with multiple spine sites 5 4
None 3 60 1 25 .08
Mild narcotic 2 40 0 0
Moderate narcotic 0 0 3 75
Abbreviations: Gy, Gray.
aMild narcotic indicated  0.5 gm/day; moderate narcotic indicates 0.5 gm to 1 gm/day; strong narcotic indicates  1 gm/
day.
bP values were determined using the chi-square test except for multiple spine sites (Fisher exact test).
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Survival estimates at 3 months and 6 months were 83%
and 62%, respectively, in the 8 Gy/1 arm and 85% and
67%, respectively, in the 30 Gy/10 arm (Table 6).
DISCUSSION
To our knowledge, this is the largest series to date compar-
ing conventionally planned single-fraction radiation
(SFRT) and conventionally planned multifraction radia-
tion (MFRT) in patients with PVBM. Radiation deliv-
ered by SFRT or MFRT was equally effective at palliating
pain from metastases to the vertebral bone. This result is
similar to what was observed in the total population of
patients with bone metastases in RTOG 97-14.4 The pain
control observed was comparable to that reported in a
group of 117 Canadian patients who received radiation
for spinal metastases.10 The largest series of patients
treated with radiation for spinal column metastases (603
patients) comes from Japan.11 Although Mizumoto et al
discuss prognostic factors, local control, and survival for
this population,11 there is little information on pain relief.
SFRT has not yet gained overwhelming support in
practice in the United States. There may be many reasons
for this—among them a reluctance to adapt a new practice
after long experience with MFRT, concerns about risks of
acute morbidity, and concerns about late CNS toxicity.
MFRT also is reimbursed at a higher rate in the United
States than SFRT.12 The current analysis provides further
evidence that SFRT for vertebral bone metastases is safe
and effective, has less acute effects, and produces no differ-
ence in late effects compared withMFRT.
Radiation-induced myelopathy is the radiation
oncologist’s greatest concern of iatrogenic toxicity of all
concerns about the potential morbidity of radiation. The
consequences of radiation damage to the spinal cord can
be devastating. Consequently, radiation oncologists are
loath to give a radiation dose anywhere near what would
be associated with a low risk of damage. It might be uncer-
tainty about the effects of 8 Gy/1 to the spinal cord that
worries some US radiation oncologists regarding this
technique. Studies from Maranzano et al using 8 Gy/1
and even two 8-Gy fractions spaced 1 week apart (16 Gy
Table 4. Pain Response 3 Months After the Start of Radiation Therapya
8-Gy Arm 30-Gy Arm
Pain Response at 3 Months No. % No. % Pb
All vertebral patients 77 100 76 100
Complete 15 19 13 17 .59
Partial 39 51 34 45
Stable 14 18 21 28
Progressive 9 12 8 10
Cervical spine patients 10 5
Complete 1 10 0 0 .42
Partial 5 50 1 20
Stable 2 20 3 60
Progressive 2 20 1 20
Thoracic spine patients 26 25
Complete 6 23 5 20 .75
Partial 14 54 13 52
Stable 5 19 4 16
Progressive 1 4 3 12
Lumbar spine patients 38 44
Complete 6 16 7 16 .45
Partial 20 52 20 45
Stable 6 16 13 30
Progressive 6 16 4 9
Patients with multiple spine sites 3 2
Complete 2 67 1 50 —
Stable 1 33 1 50
Abbreviations: Gy, Gray.
a Pain response was based on the Brief Pain Inventory worst pain score: a complete response indicates a post-RT pain
score of 0; partial response, post-RT pain score decrease 2 points from baseline score; stable response, post-RT pain
score within 1 point of baseline score; progressive response, post-RT pain score increase 2 points from baseline score.
bP values were determined using the chi-square test.
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total) for vertebral bone metastases causing spinal cord
compression have not reported any late cases of radiation-
induced myelopathy.13,14 Macbeth et al15 reported 5 cases
of radiation myelopathy among 1048 patients who had
received radiation for inoperable nonsmall cell lung can-
cer. In that study, there were 3 cases of radiation-induced
myelopathy among 524 patients who had received 17 Gy
in two 8.5 Gy fractions spaced 1 week apart, and there
were 2 cases of radiation-induced myelopathy among 153
patients who had received 39 Gy in thirteen 3 Gy
Table 5. Retreatment Rates










Time to retreatment, mo
3 10 94 2 93
6 10 68 2 74
12 15 40 3 53
36 15 15 5 16
60 15 4 5 7
No. of failures/total 19/124 6/111
P 5 0.01b
Cervical spine patients
Time to retreatment, mo
3 25 9 0 5
6 25 8 0 2
12 25 4 0 2
36 25 2 0 0
60 25 1 0 0
No. of failures/total 3/12 0/7
P 5 .16b
Thoracic spine patients
Time to retreatment, mo
3 0 35 0 33
6 0 22 0 27
12 2 16 0 17
36 5 6 3 2
60 5 2 5 1
No. of failures/total 2/44 2/40
P 5 .94b
Lumbar spine patients
Time to retreatment, mo
3 14 45 3 49
6 14 33 3 39
12 21 18 5 30
36 21 5 7 12
60 21 1 7 4
No. of failures/total 13/63 4/58
P 5 .03b
Patients with multiple spine sites
Time to retreatment, mo
3 0 5 0 6
6 0 5 0 6
12 20 2 0 4
36 20 2 0 2
60 20 0 0 2
No. of failures/total 1/5 0/6
P 5 .27b
Abbreviations: Gy, Gray.
a Estimates were based on cumulative incidence with death considered as a competing risk.
bP values were determined using the Grey test.
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Table 6. Overall Survival











3 83 103 85 94
6 62 77 67 74
12 40 50 49 54
24 26 32 26 29
60 5 5 8 8
No. of failures/total 116/124 102/111




3 92 11 71 5
6 83 10 29 2
12 33 4 29 2
24 17 2 0 0
60 8 1 0 0
No. of failures/total 11/12 7/7




3 80 35 83 33
6 50 22 68 27
12 36 16 43 17
24 27 12 25 10
60 5 2 3 1
No. of failures/total 42/44 39/40




3 83 52 86 50
6 63 40 67 39
12 43 27 53 31
24 24 15 29 17
60 5 2 10 5
No. of failures/total 58/63 52/58
Median survival, mo 10.3 12.4
P 5 .29b
Patients with multiple spine sites
Overall survival, mo
3 100 5 100 6
6 100 5 100 6
12 60 3 67 4
24 60 3 33 2
60 0 0 33 2
No. of failures/total 5/5 4/6
Median survival, mo 26.6 17.3
P 5 .46b
Abbreviations: Gy, gray.
a Kaplan-Meier estimates are listed.
bP values were determined using the log-rank test.
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fractions over 17 days. There were no reports of radiation-
induced myelopathy in the RTOG 97-14 patients.
There have been many randomized comparisons of 1
or 2 fractions of radiation versus10 fractions as palliative
therapy for painful bone metastases.1-3 Wu et al3 con-
ducted a meta-analysis that included all randomized con-
trolled trials reported between 1966 and 2000 and
observed no difference in response rates between SFRT and
MFRT. There were differences in the rates of retreatment:
Patients who received SFRT had rates of retreatment
between 11% and 25% versus patients who received
MFRT, who had retreatment rates between 0% and 12%.
The subset of patients with PVBM fromRTOG97-14 also
had similar rates of retreatment between those who received
8 Gy/1 (15%) and those who received 30 Gy/10 (5%)
To put the issue of need for retreatment in perspec-
tive, we illustrate the relative difference in total visits for
radiation between the 8 Gy/1 population and the 30 Gy/
10 population. Consider a hypothetical sample of 200
patients with PVBM in which 100 patients receive 8 Gy in
a single fraction and 100 patients receive 30 Gy in 10 frac-
tions. Assume that there is an additional visit required to
the radiation therapy department in each case for consulta-
tion, simulation, and planning. The 8 Gy/1 group will
have made 200 visits to the department; and the 30 Gy/10
group will have made 1100 visits; Then, factor in retreat-
ments: 15 from the 8 Gy/1 group will make 2 additional
visits each (30 total), and 5 patients from the 30 Gy/10
group, who will each make 11 additional visits (55 total).
In aggregate, the 8 Gy/1 group will have made 230 visits to
the radiation department, whereas the 30 Gy/10 group will
have made 1155 visits—a 5-fold difference in trips to the
radiation department. The 30 Gy/10 patient, on average,
makes 9 more visits for treatment than the SFRT patient.
The retreatment rates were greatest in those patients
who had PVBM involving the lumbar spine. Decisions on
retreatment were left to the discretion of the treating physi-
cian. The higher lumbar spine retreatment rate may have
been influenced by the absence of the spinal cord below
lumbar segment 1 (L1), which may have had an impact on
decisions to retreat. Only 23% of patients received initial
treatment with photon energies 10 MV. Higher photon
energy allows for a greater depth of penetration for a given
dose, which generally portends a better dose distribution at
depth. The lumbar spine extends deeper into the body than
the thoracic or cervical spine. In addition, more informa-
tion may be gleaned by examining allowable treatment
techniques under the radiation therapy treatment plan out-
lined by the RTOG 97-14 treatment protocol. For the cer-
vical spine, either a posterior field (treated to a depth of 5
cm or another depth, as determined from a lateral simula-
tion film) or parallel opposed lateral fields with the isocen-
ter set at mid-plane were allowed. For the thoracic spine, a
single posterior field was to be used with the treatment
depth set at the middle of the vertebral body. For the lum-
bar spine, anterior and posterior parallel opposed fields
were suggested with equal weighting. However, unequal
weighting could be used with a ratio of doses of 1:2 anteri-
or:posterior, with dose prescribed to mid-thickness of the
central axis or at the center of the target volume if unequal
weighting was to be used. Alternatively, a third option for
the lumbar spine would have been to treat with a single pos-
terior-anterior (PA) field, with dose prescribed to the mid-
vertebral body. Treatment volumes were to include the ra-
diographic abnormalities with at least a 2-cm margin.
Treatment of the entire bone was not required.1
It is reasonable to wonder, with the parameters set
for treatment, the percentages of patients who received
treatment with lower energy photons, and the treatment
volumes specified, whether the more centrally located
lumbar spine lesions would have received the desired full
and homogeneous dose of radiation. Alternately, there
may have been some form of bias on the part of participat-
ing physicians to perhaps use smaller volumes or different
dose parameters to reduce dose homogeneity in light of
concerns about the potential toxicities of SFRT. There
was nothing in the study design that required the treating
physicians to plan the field to be used before randomiza-
tion.Whether there may have been a bias in the size or ori-
entation of the fields planned based on the randomization
to SFRT orMFRT is unknown.
Another factor that was not controlled in the
RTOG 97-14 trial was initial pain management techni-
ques and pain control in the time before initiation of radi-
ation, and also how pain was managed during the course
of treatment and thereafter. Only 3 in 235 patients (1%)
reported baseline narcotic use. Randomized patients who
worked with a radiation oncologist or other health care
professional who was more cognizant of various pain
management strategies, including 1) appropriate narcotic
and non-narcotic pharmacologic pain management with
frequent pain assessment, 2) application of long-acting
analgesics, 3) judicious use of short-acting medications for
breakthrough pain, 4) the appropriate use of coanalgesics
and non-narcotic interventions, and 5) the use of pain di-
ary monitoring and other pain-management techniques
would likely have had better pain control. Various appli-
cations of non-radiation methods of management of pain
may have confounded information on pain control as
impacted by radiation technique.
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Can these data be extrapolated to patients with other
histologies? The RTOG 97-14 study enrolled only
patients with breast and prostate cancer histologies. How-
ever, in the absence of any contrary data, it appears that
the results from this study could be extrapolated to
patients who have vertebral bone metastases of other
histologies.13,14
Can these data be extrapolated to patients who have
had other local interventions such as vertebroplasty,
kyphoplasty, corpectomy or other form of stabilization
procedure? Currently the answer is unknown.
What is clear is that both regimens studied are safe
and effective for palliation of PVBM. No late grade 4
CNS toxicity was observed in either group. There were no
reports of radiation myelopathy in RTOG 97-14 patients.
GI toxicity was less in the 8 Gy/1 group. Ten percent
more patients (1 in 10) in the 8 Gy/1 group received
retreatment than in the 30 Gy/10 group. The 30 Gy/10
group required 9 more visits, on average, in the hypotheti-
cal population sample described above (allowing for
retreatment rates appropriate to each group) than the 8
Gy/1 group. Howell et al12 reported a cost analysis for
Medicare Region 1 allowable reimbursement for 7 differ-
ent schemas for the treatment of bone metastases and
demonstrated a nearly 10-fold difference in Medicare
reimbursement, depending on the technology used for
treatment, the setting for treatment delivery, and the
number of fractions used.
On a humanitarian note, the use of SFRT in this
clinical setting saves the patient and their caregivers from
having to make an additional 9 visits to the radiation on-
cology facility. It saves direct and indirect costs of addi-
tional time off of work, transportation, lodging, childcare,
and other costs. The use of SFRT also saves time for
health care providers and radiation therapists, and it
reduces linear accelerator use.
On the basis of the results from RTOG 97-14,
SFRT is safe and effective for the treatment of vertebral
bone metastases.
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